Neurona Therapeutics

We’re thrilled to announce our team’s newest preprint publication titled “Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity followed by gradual electrochemical maturation” on bioRxiv. This work, led by Neurona Therapeutics' Marina Bershteyn, PhD, Hongjun(Robin) Zhou, PhD, and Lucho Fuentealba, PhD, sheds light on the development, fate, and function of NRTX-1001 MGE pallial-type GABAergic interneurons derived from human pluripotent stem cells. Pallial or cortical interneuron loss of function leads to epilepsy and contributes to other neurological disorders. Restoration of cortical interneurons, using a novel regenerative cell therapy approach, such as NRTX-1001, represents a promising therapeutic strategy and has yielded an encouraging preliminary safety and efficacy signal in an ongoing multicenter, open-label Phase 1/2 clinical trial in drug-resistant mesial temporal lobe epilepsy. A big thank you to all the authors of this preprint, Chun Chen and Jorge Palop at the Gladstone Institute, and the incredible team at Neurona Therapeutics for their hard work and dedication in making a significant advance in our understanding of human interneuron development and regeneration. We’re excited for what’s to come as we continue to advance our cell therapy programs! Read the full paper here: https://lnkd.in/gARcMHP6 #Neurona #Epilepsy #RegenerativeMedicine

On Friday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE.

On Friday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here:

On Friday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here:

Yesterday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here: https://lnkd.in/gXJvqA-s

Today, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here: https://lnkd.in/gXJvqA-s

Marina Bershteyn, Ph.D., Director of Discovery Research, will be delivering an insightful talk at the 15th Annual Research Roundtable Meeting for the Dravet Syndrome Foundation, occurring tonight, December 5th between 6:00 and 10:00 pm. Her presentation, titled “Development of Allogeneic GABAergic Inhibitory Interneuron Cell Therapy (NRTX-1001) for Drug-resistant Focal Epilepsy,” will showcase the innovative work Neurona is doing to help those battling epilepsy. Marina’s talk will take place at 8:00 PM, alongside 5 other speakers from both academia and industry. Agenda and details: https://lnkd.in/gCDCkcTN #Neurona #RegerativeMedicine #Epilepsy

We are pleased to announce that John Hixson, M.D., Senior Medical Director, will be presenting at the American Epilepsy Society’s 2024 Annual Meeting at the Los Angeles Convention Center. Join Dr. Hixson on Sunday, December 8th, from 12:00 to 2:00 PM for his poster presentation titled, "First-in-Human Trial of NRTX-1001 Gabaergic Interneuron Cell Therapy for Drug-Resistant Focal Epilepsy – Updated Results," which will highlight the latest findings from our groundbreaking NRTX-1001 clinical investigation. Learn more about our clinical trials: NCT05135091 and NCT06422923: https://lnkd.in/gHASB7HM https://lnkd.in/gHhjBqRA #AES2024 #Neurona #Epilepsy #RegenerativeMedicine

We’re happy to announce that Derek Southwell, MD, Ph.D., Assistant Professor of Neurosurgery at Duke University and a principal investigator for two ongoing clinical trials investigating NRTX-1001 cell therapy in drug-resistant focal epilepsy, will be presenting the latest clinical data from both low and high dose cohorts at the American Epilepsy Society’s 2024 Meeting in Los Angeles, CA. Join Dr. Southwell on December 6th at 6:00 p.m. for “Fast Forward to Epilepsy Therapies in 2027,” a Special Interest Group dedicated to Translational Research. His presentation, “Cortical Interneurons: From the Developing Brain to the Operating Room,” will explore cutting-edge research for future epilepsy treatments and provide a new data update from the NRTX-1001 clinical investigation. Register for AES 2024: https://lnkd.in/ePusYH4y Learn more about our clinical trials: NCT05135091 and NCT06422923: https://lnkd.in/gHhjBqRA https://lnkd.in/gHASB7HM #AES2024 #Neurona #Epilepsy #RegenerativeMedicine

🍂 Celebrating Community, Gratitude, and Awareness This November 🍂   What a fantastic way to come together and honor Epilepsy Awareness Month with our Purple Potluck!   This cherished tradition not only filled the room with the aromas of delicious international dishes but also highlighted the strength of our diverse and compassionate team. It’s a powerful reminder of the sense of community we’ve built at Neurona—one grounded in teamwork, compassion, and passion.   As we embrace the Thanksgiving season, we are reminded of the importance of connection, care, and collaboration in everything we do. We also take this opportunity to express our heartfelt gratitude to the healthcare professionals, patients, and partners who inspire our mission every day. Your trust and dedication fuel our unwavering commitment to improving lives through innovation.   From all of us at Neurona, we wish you a Thanksgiving filled with warmth, gratitude, and cherished moments with loved ones. #Neurona #RegenerativeMedicine #EpilepsyAwarenessMonth #Epilepsy